Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

想象一下，你是一位患有晚期乳腺癌的女性，你已经尝试了所有的传统治疗方法，但效果并不理想。现在，FDA终于批准了一种新药，Datroway（datopotamab deruxtecan-dlnk），这对你来说意味着什么？让我们来看看这项重大突破的详细信息。

这是一例绝经前 HR+/HER- 晚期乳腺癌患者，该患者还伴有破溃、广泛骨转移和胸膜转移，经过八周期的化疗后胸部肿块明显缩小，骨转移病灶趋于稳定。考虑到患者较为年轻（41 ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.